AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|
16.6 C
New York
Wednesday, October 28, 2026

Tag: function

万益特于ERA发布前沿临床数据:HDx 透析疗法是替代在线血液透析滤过的优选治疗方案

苏格兰格拉斯哥, June 09, 2026 (GLOBE NEWSWIRE) -- 万益特(Vantive),作为一家拥有70年肾脏护理创新历史的重要脏器疗法公司,今日发布两项突破性临床研究:采用 泰诺佳® 透析器的 HDx 疗法,与在线血液透析滤过(OL-HDF)相比,在全因死亡率和主要心血管结局方面*表现相似(统计学上非劣效)。1,2随机对照试验MOTheR 研究、真实世界研究CONCORDIA中期数据,已于 2026 年 6 月 3–6 日在苏格兰格拉斯哥举办的第 63届欧洲肾脏协会(ERA)大会上发布。

The Frederick Arts Council Announces Call For Artists For Ballenger Creek Trail Sculpture Pedestals

FREDERICK, Md., June 8, 2026 /PRNewswire/ -- The Frederick Arts Council (FAC) invites artists to submit proposals for two sculptural pedestals for permanent installation...

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

AG1 Pro's advanced formula builds on AG1's clinically-backed formula to include additional research-backed key ingredients, including creatine, that target muscle strength, metabolic resilience, and...

Cabinetworks Group appoints Danielle Mikesell as new chief commercial officer

LIVONIA, Mich., June 8, 2026 /PRNewswire/ -- Cabinetworks Group, the country's largest privately owned cabinet manufacturer, recently announced it has appointed Danielle Mikesell as...

The CareBridge Group Pivots “Community Access Coalition” into Direct Grant Funding Engine; Invites Florida Nonprofits to Apply for $8.46 Million in Year 1 Capital

Bypassing municipal bureaucracy, the elite healthcare execution firm calls on operational nonprofits in Central Florida and Duval County to secure immediate, privately funded grants...

No Deposit Bonus Casinos for Real Money 2026: All iGaming Experts Reveal Casinos with Free Spins Bonuses

Vancouver, Canada, June 08, 2026 (GLOBE NEWSWIRE) --

 No deposit bonus casinos are receiving more attention in 2026 as players look for ways to try an online casino before spending their own money. Offers such as 50 no deposit free spins and $200 no deposit bonus 200 free spins real money allow users to test games, review bonus terms, and understand how a casino works before deciding whether to make a deposit.

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area...

Gustav Segerberg appointed new CFO of EQT AB

STOCKHOLM, June 8, 2026 /PRNewswire/ -- Gustav Segerberg has been appointed Chief Financial Officer of EQT AB, effective as of July 18, 2026. He succeeds...

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFunction